miR-497 expression, function and clinical application in cancer

Oncotarget

Volumn 7, Issue 34, 2016, Pages 55900-55911

  Yang, Gang ^a   Xiong, Guangbing ^a   Cao, Zhe ^a   Zheng, Suli ^a   You, Lei ^a   Zhang, Taiping ^a   Zhao, Yupei ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Biomarker; Carcinogenesis; Clinical application; miR 497

Indexed keywords

CYCLIN E1; CYCLINE; I KAPPA B KINASE BETA; MICRORNA; MICRORNA 497; PROTEIN BCL 2; PROTEIN BCL W; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN A; MIRN497 MICRORNA, HUMAN;

ADRENAL CORTEX CARCINOMA; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER DIAGNOSIS; CANCER GENETICS; CANCER INHIBITION; CANCER PROGNOSIS; COLORECTAL CANCER; EPIGENETICS; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE TARGETING; GENOMICS; GLIOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; KIDNEY CARCINOMA; LEUKEMIA; LIVER CELL CARCINOMA; LUNG CANCER; MELANOMA; NONHUMAN; ONCOGENE; OSTEOSARCOMA; OVARY CANCER; PANCREAS CANCER; PERITONEUM CANCER; PROSTATE CANCER; RETINOBLASTOMA; STOMACH CANCER; UTERINE CERVIX CANCER; ANIMAL; DNA METHYLATION; GENETICS; NEOPLASM; PHYSIOLOGY; PROGNOSIS;

ANIMALS; BIOMARKERS, TUMOR; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASMS; PROGNOSIS;

EID: 84983544571     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10152     Document Type: Article

References (109)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function (Reprinted from Cell 116 (2004) 281-297). Cell. 2007; 131: 11-29.
2. Lee Y, Ahn C, Han JJ, Choi H, Kim J, Yim J, Lee J, Provost P, Radmark O, Kim S, Kim VN. The nuclear RNase III Drosha initiates microRNA processing. Nature. 2003; 425: 415-419.
3. Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature. 2001; 409: 363-366.
4. Bohnsack MT, Czaplinski K, Gorlich D. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA. 2004; 10: 185-191.
5. Hutvagner G, McLachlan J, Pasquinelli AE, Balint E, Tuschl T, Zamore PD. A cellular function for the RNAinterference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science. 2001; 293: 834-838.
6. Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol. 2009; 11: 228-234.
7. Mourelatos Z, Dostie J, Paushkin S, Sharma A, Charroux B, Abel L, Rappsilber J, Mann M, Dreyfuss G. miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs. Genes Dev. 2002; 16: 720-728.
8. Gregory RI, Chendrimada TP, Cooch N, Shiekhattar R. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell. 2005; 123: 631-640.
9. Ruan K, Fang XG, Ouyang GL. MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett. 2009; 285: 116-126.
10. Itesako T, Seki N, Yoshino H, Chiyomaru T, Yamasaki T, Hidaka H, Yonezawa T, Nohata N, Kinoshita T, Nakagawa M, Enokida H. The microRNA expression signature of bladder cancer by deep sequencing: the functional significance of the miR-195/497 cluster. Plos One. 2014; 9: e84311.
11. Finnerty JR, Wang WX, Hebert SS, Wilfred BR, Mao GG, Nelson PT. The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases. J Mol Biol. 2010; 402: 491-509.
12. Aqeilan RI, Calin GA, Croce CM. miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Diff. 2010; 17: 215-220.
13. He JF, Luo YM, Wan XH, Jiang DQ. Biogenesis of MiRNA-195 and its role in biogenesis, the cell cycle, and apoptosis. J Biochem Mol Toxicol. 2011; 25: 404-408.
14. Yang CH, Wang C, Chen X, Chen SD, Zhang YN, Zhi F, Wang JJ, Li LM, Zhou XJ, Li NY, Pan H, Zhang JF, Zen K, et al. Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Int J Cancer. 2013; 132: 116-127.
15. Li D, Zhao YL, Liu CX, Chen XN, Qi YT, Jiang Y, Zou C, Zhang XL, Liu SY, Wang XJ, Zhao D, Sun QA, Zeng ZB, et al. Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. Clin Cancer Res. 2011; 17: 1722-1730.
16. Zhao W-Y, Wang Y, An Z-J, Shi C-G, Zhu G-A, Wang B, Lu M-Y, Pan C-K, Chen P. Downregulation of miR-497 promotes tumor growth and angiogenesis by targeting HDGF in non-small cell lung cancer. Biochem Biophys Res Commun. 2013; 435: 466-471.
17. Zhao XL, Zhao ZH, Xu WC, Hou JQ, Du XY. Downregulation of miR-497 is associated with poor prognosis in renal cancer. Int J Clin Exp Pathol. 2015; 8: 758-764.
18. Guo JM, Miao Y, Xiao BX, Huan R, Jiang Z, Meng D, Wang YJ. Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J Gastroenterol Hepatol. 2009; 24: 652-657.
19. Du ML, Shi DN, Yuan L, Li PC, Chu HY, Qin C, Yin CJ, Zhang ZD, Wang ML. Circulating miR-497 and miR-663b in plasma are potential novel biomarkers for bladder cancer. Sci Rep. 2015; 5: 10437.
20. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, Zeng YX, Shao JY. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA. 2008; 14: 2348-2360.
21. Tahiri A, Leivonen SK, Luders T, Steinfeld I, Aure MR, Geisler J, Makela R, Nord S, Riis MLH, Yakhini Z, Sahlberg KK, Borresen-Dale AL, Perala M, et al. Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors. Carcinogenesis. 2014; 35: 76-85.
22. Luo QF, Li XY, Gao Y, Long Y, Chen L, Huang YX, Fang L. MiRNA-497 regulates cell growth and invasion by targeting cyclin E1 in breast cancer. Cancer Cell Int. 2013; 13: 95.
23. Chang YY, Kuo WH, Hung JH, Lee CY, Lee YH, Chang YC, Lin WC, Shen CY, Huang CS, Hsieh FJ, Lai LC, Tsai MH, Chang KJ, et al. Deregulated microRNAs in triplenegative breast cancer revealed by deep sequencing. Mol Cancer. 2015; 14: 36.
24. Lehmann U, Streichert T, Otto B, Albat C, Hasemeier B, Christgen H, Schipper E, Hille U, Kreipe HH, Langer F. Identification of differentially expressed microRNAs in human male breast cancer. BMC Cancer. 2010; 10: 109.
25. Pinto R, De Summa S, Danza K, Popescu O, Paradiso A, Micale L, Merla G, Palumbo O, Carella M, Tommasi S. MicroRNA expression profiling in male and female familial breast cancer. Br J Cancer. 2014; 111: 2361-2368.
26. Li WD, Jin XJ, Deng XB, Zhang G, Zhang BQ, Ma L. The putative tumor suppressor microRNA-497 modulates gastric cancer cell proliferation and invasion by repressing eIF4E. Biochem Biophys Res Commun. 2014; 449: 235-240.
27. Menigatti M, Staiano T, Manser CN, Bauerfeind P, Komljenovic A, Robinson M, Jiricny J, Buffoli F, Marra G. Epigenetic silencing of monoallelically methylated miRNA loci in precancerous colorectal lesions. Oncogenesis. 2013; 2: e56.
28. Xie Y, Wei R-R, Huang G-L, Zhang M-Y, Yuan Y-F, Wang H-Y. Checkpoint kinase 1 is negatively regulated by miR-497 in hepatocellular carcinoma. Med Oncol. 2014; 31: 844.
29. Xu J, Wang T, Cao Z, Huang H, Li J, Liu W, Liu S, You L, Zhou L, Zhang T, Zhao Y. MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis. Oncotarget. 2014; 5: 6983-6993. doi: 10.18632/oncotarget.2184.
30. Ozata DM, Caramuta S, Velazquez-Fernandez D, Akcakaya P, Xie H, Hoog A, Zedenius J, Backdahl M, Larsson C, Lui WO. The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. Endocr Relat Cancer. 2011; 18: 643-655.
31. Kunz M. (2013). MicroRNAs in melanoma biology. In: Schmitz U, Wolkenhauer O and Vera J, eds. Microrna cancer regulation: advanced concepts, bioinformatics and systems biology tools. (Dordrecht: Springer), pp. 103-120.
32. Delfino KR, Rodriguez-Zas SL. Transcription factor microRNA-target gene networks associated with ovarian cancer survival and recurrence. Plos One. 2013; 8: e58608.
33. Luo M, Shen DX, Zhou XN, Chen XD, Wang W. MicroRNA-497 is a potential prognostic marker in human cervical cancer and functions as a tumor suppressor by targeting the insulin-like growth factor 1 receptor. Surgery. 2013; 153: 836-847.
34. Jiang YS, Meng QH, Qi JQ, Shen HY, Sun SC. MiR-497 promotes metastasis of colorectal cancer cells through Nrdp1 inhibition. Tumour Biol. 2015; 36: 7641-7647.
35. Guo ST, Jiang CC, Wang GP, Li YP, Wang CY, Guo XY, Yang RH, Feng Y, Wang FH, Tseng HY, Thorne RF, Jin L, Zhang XD. MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer. Oncogene. 2013; 32: 1910-1920.
36. Wang L, Jiang CF, Li DM, Ge X, Shi ZM, Li CY, Liu X, Yin Y, Zhen LL, Liu LZ, Jiang BH. MicroRNA-497 inhibits tumor growth and increases chemosensitivity to 5-fluorouracil treatment by targeting KSR1. Oncotarget. 2016; 7: 2660-2671. doi: 10.18632/oncotarget.6545.
37. Qiu YY, Hu Q, Tang QF, Feng W, Hu SJ, Liang B, Peng W, Yin PH. MicroRNA-497 and bufalin act synergistically to inhibit colorectal cancer metastasis. Tumour Biol. 2014; 35: 2599-2606.
38. Zhang YJ, Zhang DH, Wang F, Xu DF, Guo Y, Cui W. Serum miRNAs panel (miR-16-2*, miR-195, miR-2861, miR-497) as novel non-invasive biomarkers for detection of cervical cancer. Sci Rep. 2015; 5: 17942.
39. Maura F, Cutrona G, Mosca L, Matis S, Lionetti M, Fabris S, Agnelli L, Colombo M, Massucco C, Ferracin M, Zagatti B, Reverberi D, Gentile M, et al. Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia. Leuk Lymphoma. 2015; 56: 3150-3158.
40. Lan J, Xue YJ, Chen HR, Zhao SH, Wu ZJ, Fang J, Han C, Lou MQ. Hypoxia-induced miR-497 decreases glioma cell sensitivity to TMZ by inhibiting apoptosis. FEBS Lett. 2014; 588: 3333-3339.
41. Troppan K, Wenzl K, Pichler M, Pursche B, Schwarzenbacher D, Feichtinger J, Thallinger GG, Beham-Schmid C, Neumeister P, Deutsch A. miR-199a and miR-497 are associated with better overall survival due to increased chemosensitivity in diffuse large B-cell lymphoma patients. Int J Mol Sci. 2015; 16: 18077-18095.
42. Slattery M, Zhou TY, Yang L, Machado ACD, Gordan R, Rohs R. Absence of a simple code: how transcription factors read the genome. Trends Biochem Sci. 2014; 39: 381-399.
43. Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ, Davuluri R, Liu CG, Croce CM, Negrini M, Calin GA, Ivan M. A microRNA signature of hypoxia. Mol Cell Biol. 2007; 27: 1859-1867.
44. Goda N, Ryan HE, Khadivi B, McNulty W, Rickert RC, Johnson RS. Hypoxia-inducible factor 1 alpha is essential for cell cycle arrest during hypoxia. Mol Cell Biol. 2003; 23: 359-369.
45. Xu XF, Jia RB, Zhou YX, Song X, Wang J, Qian GX, Ge SF, Fan XQ. Microarray-based analysis: identification of hypoxia-regulated microRNAs in retinoblastoma cells. Int J Oncol. 2011; 38: 1385-1393.
46. Wu ZH, Cai XH, Huang CG, Xu J, Liu A. miR-497 suppresses angiogenesis in breast carcinoma by targeting HIF-1 alpha. Oncol Rep. 2016; 35: 1696-1702.
47. Chen LF, Greene WC. Shaping the nuclear action of NFkappa B. Nat Rev Mol Cell Biol. 2004; 5: 392-401.
48. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NFkappa B-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA. 2006; 103: 12481-12486.
49. Wei W, Zhang WY, Bai JB, Zhang HX, Zhao YY, Li XY, Zhao SH. The NF-kappa B-modulated microRNAs miR-195 and miR-497 inhibit myoblast proliferation by targeting Igf1r, Insr and cyclin genes. J Cell Sci. 2016; 129: 39-50.
50. Mechtler P, Singhal R, Kichina JV, Bard JE, Buck MJ, Kandel ES. MicroRNA analysis suggests an additional level of feedback regulation in the NF-kappa B signaling cascade. Oncotarget. 2015; 6: 17097-17106. doi: 10.18632/oncotarget.4005.
51. Liu XL, Chen XY, Yu XF, Tao YG, Bode AM, Dong ZG, Cao Y. Regulation of microRNAs by epigenetics and their interplay involved in cancer. J Exp Clin Cancer Res. 2013; 32: 8.
52. Lopez-Serra P, Esteller M. DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer. Oncogene. 2012; 31: 1609-1622.
53. Dominguez-Salas P, Moore SE, Cole D, da Costa KA, Cox SE, Dyer RA, Fulford AJC, Innis SM, Waterland RA, Zeisel SH, Prentice AM, Hennig BJ. DNA methylation potential: dietary intake and blood concentrations of onecarbon metabolites and cofactors in rural African women. Am J Clin Nutr. 2013; 97: 1217-1227.
54. Cook RJ, Wagner C. Glycine N-methyltransferase is a folate binding-protein of rat-liver cytosol. Proc Natl Acad Sci USA. 1984; 81: 3631-3634.
55. Storch KJ, Wagner DA, Young VR. Methionine kinetics in adult men-effects of dietary betaine on L-H-2(3)-methyl-1-C-13 methionine. Am J Clin Nutr. 1991; 54: 386-394.
56. Varela-Rey M, Martinez-Lopez N, Fernandez-Ramos D, Embade N, Calvisi DF, Woodhoo A, Rodriguez J, Fraga MF, Julve J, Rodriguez-Millan E, Frades I, Torres L, Luka Z, et al. Fatty liver and fibrosis in glycine N-methyltransferase knockout mice is prevented by nicotinamide. Hepatology. 2010; 52: 105-114.
57. Cai DM, Jia YM, Lu JY, Yuan MJ, Sui SY, Song HG, Zhao RQ. Maternal dietary betaine supplementation modifies hepatic expression of cholesterol metabolic genes via epigenetic mechanisms in newborn piglets. Br J Nutr. 2014; 112: 1459-1468.
58. He XX, Kuang SZ, Liao JZ, Xu CR, Chang Y, Wu YL, Gong J, Tian DA, Guo AY, Lin JS. The regulation of microRNA expression by DNA methylation in hepatocellular carcinoma. Mol Biosyst. 2015; 11: 532-539.
59. Xu SH, Fu GB, Tao Z, OuYang J, Kong FF, Jiang BH, Wan XP, Chen K. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1. Oncotarget. 2015; 6: 26457-26471. doi: 10.18632/oncotarget.4762.
60. Flavin RJ, Smyth PC, Laios A, O'Toole SA, Barrett C, Finn SP, Russell S, Ring M, Denning KM, Li J, Aherne ST, Sammarae DA, Aziz NA, et al. Potentially important microRNA cluster on chromosome 17p13.1 in primary peritoneal carcinoma. Mod Pathol. 2009; 22: 197-205.
61. Vaishnavi V, Manikandan M, Tiwary BK, Munirajan AK. Insights on the functional impact of microRNAs present in autism-associated copy number variants. Plos One. 2013; 8: e56781.
62. Karreth FA, Tay Y, Perna D, Ala U, Tan SM, Rust AG, DeNicola G, Webster KA, Weiss D, Perez-Mancera PA, Krauthammer M, Halaban R, Provero P, et al. In vivo identification of tumor-suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell. 2011; 147: 382-395.
63. Salmena L, Poliseno L, Tay Y, Kats L, PandolfiPP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell. 2011; 146: 353-358.
64. Xu J-W, Wang T-X, You L, Zheng L-F, Shu H, Zhang T-P, Zhao Y-P. Insulin-like growth factor 1 receptor (IGF-1R) as a target of MiR-497 and plasma IGF-1R levels associated with TNM stage of pancreatic cancer. Plos One. 2014; 9: e92847.
65. Wang SM, Mo YX, Midorikawa K, Zhang Z, Huang GW, Ma N, Zhao WL, Hiraku Y, Oikawa S, Murata M. The potent tumor suppressor miR-497 inhibits cancer phenotypes in nasopharyngeal carcinoma by targeting ANLN and HSPA4L. Oncotarget. 2015; 6: 35893-35907. doi: 10.18632/oncotarget.5651.
66. Shen L, Li J, Xu JP, Ma J, Li H, Xiao XG, Zhao JY, Fang L. miR-497 induces apoptosis of breast cancer cells by targeting Bcl-w. Exp Ther Med. 2012; 3: 475-480.
67. Yan J-J, Zhang Y-N, Liao J-Z, Ke K-P, Chang Y, Li P-Y, Wang M, Lin J-S, He X-X. MiR-497 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting VEGFA and AEG-1. Oncotarget. 2015; 6: 29527-29542 doi: 10.18632/oncotarget.5012.
68. Wang W, Ren F, Wu QH, Jiang DZ, Li HJ, Shi HR. MicroRNA-497 suppresses angiogenesis by targeting vascular endothelial growth factor A through the PI3K/AKT and MAPK/ERK pathways in ovarian cancer. Oncol Rep. 2014; 32: 2127-2133.
69. Wei CK, Luo QF, Sun XG, Li DF, Song HM, Li XY, Song JL, Hua KY, Fang L. microRNA-497 induces cell apoptosis by negatively regulating Bcl-2 protein expression at the posttranscriptional level in human breast cancer. Int J Clin Exp Pathol. 2015; 8: 7729-7739.
70. Wang L, Li B, Li L, Wang T. MicroRNA-497 suppresses proliferation and induces apoptosis in prostate cancer cells. Asian Pac J Cancer Prev. 2013; 14: 3499-3502.
71. Gu AQ, Lu JH, Wang WM, Shi CL, Han BH, Yao M. Role of miR-497 in VEGF-A-mediated cancer cell growth and invasion in non-small cell lung cancer. Int J Biochem Cell Biol. 2016; 70: 118-125.
72. Shao XJ, Miao MH, Xue J, Ji XQ, Zhu H. The downregulation of microRNA-497 contributes to cell growth and cisplatin resistance through PI3K/Akt pathway in osteosarcoma. Cell Physiol Biochem. 2015; 36: 2051-2062.
73. Farazi TA, Hoell JI, Morozov P, Tuschl T. MicroRNAs in human cancer. Adv Exp Med Biol. 2013; 774: 1-20.
74. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281-297.
75. Siddiqui WA, Ahad A, Ahsan H. The mystery of BCL2 family: Bcl-2 proteins and apoptosis: an update. Arch Toxicol. 2015; 89: 289-317.
76. Yin KJ, Deng Z, Huang HR, Hamblin M, Xie CQ, Zhang JF, Chen YE. miR-497 regulates neuronal death in mouse brain after transient focal cerebral ischemia. Neurobiol Dis. 2010; 38: 17-26.
77. Zhu W, Zhu DX, Lu SQ, Wang TS, Wang J, Jiang BH, Shu YQ, Liu P. miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol. 2012; 29: 384-391.
78. Um HD. Bcl-2 family proteins as regulators of cancer cell invasion and metastasis: a review focusing on mitochondrial respiration and reactive oxygen species. Oncotarget. 2015; 7: 5193-5203. doi: 10.18632/oncotarget.6405.
79. Saharinen P, Eklund L, Pulkki K, Bono P, Alitalo K. VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med. 2011; 17: 347-362.
80. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009; 15: 220-231.
81. Tu Y, Liu L, Zhao D, Liu Y, Ma X, Fan Y, Wan L, Huang T, Cheng Z, Shen B. Overexpression of miRNA-497 inhibits tumor angiogenesis by targeting VEGFR2. Sci Rep. 2015; 5: 13827.
82. Dupont J, LeRoith D. Insulin and insulin-like growth factor I receptors: similarities and differences in signal transduction. Horm Res. 2001; 55: 22-26.
83. Shen MR, Hsu YM, Hsu KF, Chen YF, Tang MJ, Chou CY. Insulin-like growth factor 1 is a potent stimulator of cervical cancer cell invasiveness and proliferation that is modulated by alpha(v)beta(3) integrin signaling. Carcinogenesis. 2006; 27: 962-971.
84. Singh P, Alex JM, Bast F. Insulin receptor (IR) and insulinlike growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer. Med Oncol. 2014; 31: 805.
85. Wang X, Wang MC, Li HM, Lan X, Liu L, Li JX, Li Y, Li J, Yi J, Du XJ, Yan JD, Han Y, Zhang FJ, et al. Upregulation of miR-497 induces hepatic insulin resistance in E3 rats with HFD-MetS by targeting insulin receptor. Mol Cell Endocrinol. 2015; 416: 57-69.
86. Rosenberg E, Demopoulos RI, Zeleniuch-Jacquotte A, Yee H, Sorich J, Speyer JL, Newcomb EW. Expression of cell cycle regulators p57(KIP2), cyclin D1, and cyclin E in epithelial ovarian tumors and survival. Hum Pathol. 2001; 32: 808-813.
87. Möröy T, Geisen C. Cyclin E. Int J Biochem Cell Biol. 2004; 36: 1424-1439.
88. Schraml P, Bucher C, Bissig H, Nocito A, Haas P, Wilber K, Seelig S, Kononen J, Mihatsch MJ, Dirnhofer S, Sauter G. Cyclin E overexpression and amplification in human tumours. J Pathol. 2003; 200: 375-382.
89. Furuta M, Kozaki K, Tanimoto K, Tanaka S, Arii S, Shimamura T, Niida A, Miyano S, Inazawa J. The tumorsuppressive miR-497-195 cluster targets multiple cell-cycle regulators in hepatocellular carcinoma. Plos One. 2013; 8: e60155.
90. Han ZY, Zhang YB, Yang QY, Liu BB, Wu JJ, Zhang YJ, Yang CF, Jiang YG. miR-497 and miR-34a retard lung cancer growth by co-inhibiting cyclin E1 (CCNE1). Oncotarget. 2015; 6: 13149-13163. doi: 10.18632/oncotarget.3693.
91. Yadav S, Pandey A, Shukla A, Talwelkar SS, Kumar A, Pant AB, Parmar D. miR-497 and miR-302b Regulate Ethanol-induced Neuronal Cell Death through BCL2 Protein and Cyclin D2. J Biol Chem. 2011; 286: 37347-37357.
92. Sato T, Yamamoto T, Sehara-Fujisawa A. miR-195/497 induce postnatal quiescence of skeletal muscle stem cells. Nat Commun. 2014; 5: 4597.
93. Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M. The I kappa B kinase complex (IKK) contains two kinase subunits, IKK alpha and IKK beta, necessary for I kappa B phosphorylation and NF-kappa B activation. Cell. 1997; 91: 243-252.
94. Maeda S, Omata M. Inflammation and cancer: role of nuclear factor-kappaB activation. Cancer Sci. 2008; 99: 836-842.
95. Kong XJ, Duan LJ, Qian XQ, Xu D, Liu HL, Zhu YJ, Qi J. Tumor-suppressive microRNA-497 targets IKK beta to regulate NF-kappa B signaling pathway in human prostate cancer cells. Am J Cancer Res. 2015; 5: 1795-1804.
96. Caramuta S, Lee L, Ozata DM, Akcakaya P, Xie H, Hoog A, Zedenius J, Backdahl M, Larsson C, Lui WO. Clinical and functional impact of TARBP2 over-expression in adrenocortical carcinoma. Endocr Relat Cancer. 2013; 20: 551-564.
97. Zheng DL, Radziszewska A, Woo P. MicroRNA 497 modulates interleukin 1 signalling via the MAPK/ERK pathway. FEBS Lett. 2012; 586: 4165-4172.
98. Wang W, Ren F, Wu QH, Jiang DZ, Li HJ, Peng Z, Wang JL, Shi HR. MicroRNA-497 inhibition of ovarian cancer cell migration and invasion through targeting of SMAD specific E3 ubiquitin protein ligase 1. Biochem Biophys Res Commun. 2014; 449: 432-437.
99. Creevey L, Ryan J, Harvey H, Bray IM, Meehan M, Khan AR, Stallings RL. MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1. Mol Cancer. 2013; 12: 23.
100. Ruan WD, Wang P, Feng SQ, Xue Y, Zhang B. MicroRNA-497 inhibits cell proliferation, migration, and invasion by targeting AMOT in human osteosarcoma cells. Onco Targets Ther. 2016; 9: 303-313.
101. Hao YW, Chun A, Cheung K, Rashidi B, Yang XL. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem. 2008; 283: 5496-5509.
102. Huang CB, Ma RJ, Yue J, Li N, Li ZX, Qi DL. MiR-497 suppresses YAP1 and inhibits tumor growth in non-small cell lung cancer. Cell Physiol Biochem. 2015; 37: 342-352.
103. Rapa I, Votta A, Felice B, Righi L, Giorcelli J, Scarpa A, Speel EJM, Scagliotti GV, Papotti M, Volante M. Identification of microRNAs differentially expressed in lung carcinoid subtypes and progression. Neuroendocrinology. 2015; 101: 246-255.
104. Feinmesser M, Benbassat C, Meiri E, Benjamin H, Lebanony D, Lebenthal Y, de Vries L, Drozd T, Spector Y. Specific microRNAs differentiate adrenocortical adenomas from carcinomas and correlate with Weiss histopathologic system. Appl Immunohistochem Mol Morphol. 2015; 23: 522-531.
105. Li ZC, Lu J, Luo Y, Li SN, Chen MS. High association between human circulating microRNA-497 and acute myocardial infarction. ScientificWorldJournal. 2014; 2014: 931845.
106. Wang SH, Li HJ, Wang JJ, Wang D. Expression of microRNA-497 and its prognostic significance in human breast cancer (Retracted article. See vol. 10, pg. 9, 2015). Diagn Pathol. 2013; 8: 9.
107. Lionetti M, Musto P, Di Martino MT, Fabris S, Agnelli L, Todoerti K, Tuana G, Mosca L, Cantafio MEG, Grieco V, Bianchino G, D'Auria F, Statuto T, et al. Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia. Clin Cancer Res. 2013; 19: 3130-3142.
108. Li XX, Zeng Z, Li Q, Xu QL, Xie JH, Hao HX, Luo GJ, Liao WJ, Bin JP, Huang XB, Liao YL. Inhibition of microRNA-497 ameliorates anoxia/reoxygenation injury in cardiomyocytes by suppressing cell apoptosis and enhancing autophagy. Oncotarget. 2015; 6: 18829-18844. doi: 10.18632/oncotarget.4774.
109. Poell JB, van Haastert RJ, de Gunst T, Schultz IJ, Gommans WM, Verheul M, Cerisoli F, van Noort PI, Prevost GP, Schaapveld RQJ, Cuppen E. A functional screen identifies specific microRNAs capable of inhibiting human melanoma cell viability. Plos One. 2012; 7: e43569.